Block has provided more than $200 billion in credit to customers across its Cash App Borrow, Afterpay and Square Loans products.By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions .Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.The company has extended credit to Ame ...

Block has provided more than $200 billion in credit to customers across its Cash App Borrow, Afterpay and Square Loans products.By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions .Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.The company has extended credit to Ame ...

Core Viewpoint - Reconnaissance Energy Africa Ltd. has successfully completed an underwritten offering, raising gross proceeds of C$36,800,098 to fund its capital program for 2026, which includes various exploration and operational activities [1][4]. Financing Details - The offering was led by Research Capital Corporation as the lead underwriter, with participation from Canaccord Genuity Corp. and Haywood Securities Inc. [2] - A total of 38,736,945 units were issued at a price of C$0.95 per unit, each consisting of one common share and one-half of a common share purchase warrant [3]. Use of Proceeds - The net proceeds from the offering will be allocated to: - Conducting extensive production tests and installing production casing at the Kavango West 1X discovery well - Advancing operations to spud the Kavango appraisal well - Re-processing seismic data at the Loba discovery and exploration inventory on the Ngulu block in Gabon - General corporate purposes and working capital [4][8]. Shareholder Changes - BW Energy Limited acquired 2,315,780 units in the offering, increasing its holdings to 26,338,780 common shares and 25,180,890 warrants, representing approximately 6.96% of the issued shares on an undiluted basis [5][7]. - Prior to the offering, BW Energy held approximately 7.08% of the issued shares, indicating a slight dilution in percentage ownership post-offering [6][7]. Insider Participation - Certain insiders of the company acquired a total of 107,000 units in the offering, which is classified as a related-party transaction [11]. - The company is relying on exemptions from formal valuation and minority security holder approval requirements due to the offering's fair market value being below 25% of its market capitalization [11]. Underwriter Compensation - The underwriters received a cash fee of 6% of the gross proceeds and additional broker warrants to acquire 2,148,045 common shares [13]. - An advisory fee of C$21,800 was also paid to the underwriters, along with advisory broker warrants [13]. Company Overview - ReconAfrica is engaged in oil and gas exploration in the Damara Fold Belt and Kavango Rift Basin, holding petroleum licenses over approximately 13 million contiguous acres [15].

Core Viewpoint - Block & Leviton is investigating Travere Therapeutics, Inc. for potential securities law violations following a significant drop in its stock price after the FDA extended the review timeline for its drug FILSPARI [2][4]. Group 1: Company Overview - Travere Therapeutics, Inc. is facing scrutiny after its shares were halted from trading due to a more than 30% decline in intraday trading on January 13, 2026 [2]. - The U.S. FDA has set a new PDUFA target action date of April 13, 2026, for the supplemental New Drug Application for FILSPARI, indicating that additional data is required to assess clinical benefits [2]. Group 2: Investigation Details - Block & Leviton is examining whether Travere Therapeutics adequately disclosed the risks associated with the FDA review extension and if prior communications were misleading [2][4]. - The firm is considering filing an action to recover losses for investors who have been affected by the stock price decline [4]. Group 3: Investor Eligibility - Any investor who purchased common stock of Travere Therapeutics and experienced a loss may be eligible to participate in the investigation, regardless of whether they have sold their shares [3]. Group 4: Whistleblower Information - Individuals with non-public information about Travere Therapeutics are encouraged to assist in the investigation or report to the SEC under the whistleblower program, with potential rewards of up to 30% of any successful recovery [6]. Group 5: Firm Reputation - Block & Leviton is recognized as a leading securities class action firm, having recovered billions for defrauded investors and representing many top institutional investors [7].

Core Viewpoint - Halper Sadeh LLC is investigating potential breaches of fiduciary duties by certain officers and directors of Block, Inc. (NYSE: XYZ) towards shareholders [1] Group 1: Legal Actions and Shareholder Rights - Long-term shareholders of Block may seek corporate governance reforms, return of funds, court-approved financial incentives, or other benefits [2] - The firm operates on a contingent fee basis, meaning shareholders would not incur out-of-pocket legal fees [2] Group 2: Importance of Shareholder Participation - Shareholder involvement is crucial for improving company policies, practices, and oversight, which can lead to enhanced shareholder value [3] Group 3: Firm's Background and Achievements - Halper Sadeh LLC represents global investors affected by securities fraud and corporate misconduct, having recovered millions for defrauded investors [4]

Core Viewpoint - A securities fraud lawsuit has been filed against Agilon Health, Inc. (NYSE: AGL) following a significant drop in its stock price after the resignation of its CEO and the withdrawal of its financial guidance for 2025 [1][2]. Group 1: Company Developments - Agilon Health's shares fell over 25% in after-hours trading on August 4, 2025, due to the unexpected resignation of CEO Steven Sell and the withdrawal of the company's full-year 2025 financial guidance [2]. - The company cited unexpected medical cost pressures and downward adjustments to prior revenue estimates as reasons for these actions [2]. Group 2: Legal Allegations - The lawsuit alleges that Agilon Health recklessly issued guidance for 2025 that was unlikely to be achieved, given known industry challenges [3]. - It is claimed that Agilon materially overstated the financial benefits from strategic actions intended to mitigate risks, leading to misleading statements about its business and prospects [3]. Group 3: Investor Information - Investors who purchased Agilon Health common stock between February 26, 2025, and August 4, 2025, may be eligible to recover losses, regardless of whether they sold their shares [4]. - The deadline to seek appointment as lead plaintiff in the lawsuit is March 2, 2026, and a class has not yet been certified [5]. Group 4: Whistleblower Information - Individuals with non-public information about Agilon Health are encouraged to assist in the investigation or report to the SEC under the whistleblower program, with potential rewards of up to 30% of any successful recovery [6]. Group 5: Legal Firm Background - Block & Leviton is recognized as a leading securities class action firm, having recovered billions for defrauded investors and representing many top institutional investors [7].

Boston, Massachusetts--(Newsfile Corp. - January 14, 2026) - Block & Leviton reminds investors that a securities fraud lawsuit has been filed against CoreWeave, Inc. (NASDAQ: CRWV) and certain of its executives. Investors who have lost money in their CoreWeave investment should contact the firm to learn more about how they might recover those losses. For more details, visit https://blockleviton.com/cases/crwv.What is this all about?CoreWeave presents itself as an AI hyperscale cloud provider that generates ...

Core Viewpoint - Orosur Mining Inc has announced a block listing update regarding its unlisted warrants, detailing the balance of unallotted securities and changes since the last return [1] Summary by Relevant Sections Company Information - Company Name: Orosur Mining Inc [1] - Contact: Louis Castro, Executive Chairman [1] Scheme Details - Name of Scheme: Unlisted warrants [1] - Period of Return: From July 14, 2025, to January 14, 2026 [1] Securities Information - Previous Balance of Unallotted Securities: 15,203,116 [1] - Increase in Block Scheme: 19,586,444 [1] - Securities Issued/Allotted During Period: 15,036,912 [1] - Remaining Balance of Unallotted Securities: 19,752,648 [1]

Core Viewpoint - Block & Leviton is investigating Travere Therapeutics, Inc. for potential securities law violations following a significant drop in share price after the FDA extended the review timeline for a key drug application [1][2]. Group 1: Company Overview - Travere Therapeutics, Inc. experienced a trading halt after its shares fell over 30% on January 13, 2026, due to the FDA's extension of the review timeline for the supplemental New Drug Application for FILSPARI [2]. - The FDA set a new PDUFA target action date of April 13, 2026, citing that additional responses from Travere constituted a major amendment and required further data to assess clinical benefit [2]. Group 2: Investigation Details - Block & Leviton is examining whether Travere Therapeutics adequately disclosed the risks associated with the review extension and if prior communications regarding the regulatory timeline were misleading [2][4]. - The firm is considering filing an action to recover losses for investors who have been affected by the decline in share value [4]. Group 3: Investor Eligibility - Any individual who purchased common stock of Travere Therapeutics and has experienced a decline in share value may be eligible to participate in the investigation, regardless of whether they have sold their investment [3]. Group 4: Whistleblower Information - Individuals with non-public information about Travere Therapeutics are encouraged to assist in the investigation or report to the SEC under the whistleblower program, potentially receiving rewards of up to 30% of any successful recovery [6]. Group 5: Firm's Reputation - Block & Leviton is recognized as a leading securities class action firm, having recovered billions for defrauded investors and representing many top institutional investors [7].

Core Viewpoint - Mizuho Securities suggests that fintech companies such as SoFi, Affirm, and Block may gain advantages from Trump's proposed cap on interest rates [1] Company and Industry Summary - Fintech companies like SoFi, Affirm, and Block are positioned to benefit from regulatory changes regarding interest rate caps [1]